中等度から重度の活動性クローン病の小児参加者におけるグセルクマブの研究 (MACARONI-23)
小児クローン病における有効性を確立するためのIL-23経路のp19阻害の第3相、多施設共同、ランダム化プラットフォーム研究
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90048
- 募集
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- 募集
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University
-
Atlanta、Georgia、アメリカ、30342
- 募集
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202-5225
- 募集
- Riley Hospital for Children
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07960
- 募集
- Goryeb Children's Hospital
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- Icahn School of Medicine at Mount Sinai
-
New York、New York、アメリカ、10032
- 募集
- Columbia University Medical Center
-
New York、New York、アメリカ、10021-5663
- 募集
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton、Ohio、アメリカ、45404
- 募集
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester、Vermont、アメリカ、05446
- 募集
- University of Vermont Medical Center
-
-
-
-
-
Glasgow、イギリス、G51 4TF
- 募集
- Royal Hospital for Sick Children
-
London、イギリス、WC1N 3JH
- 募集
- Great Ormond Street Hospital
-
Manchester、イギリス、M13 9WL
- 募集
- Royal Manchester Children's Hospital
-
Manchester、イギリス、M13 9WL
- 募集
- Nowgen Centre, Research and Innovation
-
Oxford、イギリス、OX3 9DU
- 募集
- John Radcliffe Hospital
-
Sheffield、イギリス、S10 2TH
- 募集
- Sheffield Children's Hospital
-
-
-
-
-
Beersheba、イスラエル、84101
- 募集
- Soroka University Medical Center
-
Be’er Ya‘aqov、イスラエル、70300
- 募集
- Shamir Medical Center Assaf Harofeh
-
Jerusalem、イスラエル、9103102
- 募集
- Shaare Zedek Medical Center
-
Jerusalem、イスラエル、9124001
- 募集
- Hadassah Medical Center
-
Petah Tikva、イスラエル、4920235
- 募集
- Schneider Children's Medical Center
-
Rehovot、イスラエル、761001
- 募集
- Kaplan Medical Center
-
-
-
-
-
Alessandria、イタリア、15121
- 募集
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo、イタリア、24127
- 募集
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna、イタリア、40124
- 募集
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence、イタリア、50139
- 募集
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan、イタリア、20154
- 募集
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma、イタリア、161
- 募集
- AOU Policlinico Umberto I
-
-
-
-
-
Rotterdam、オランダ、3015 GD
- 募集
- Erasmus Medisch Centrum
-
-
-
-
-
Nedlands、オーストラリア、6009
- 募集
- Perth Children's Hospital
-
South Brisbane、オーストラリア、4101
- 募集
- Mater Hospital Brisbane
-
Westmead、オーストラリア、2145
- 募集
- The Children's Hospital at Westmead
-
-
-
-
-
Vienna、オーストリア、1090
- 募集
- AKH - Medizinische Universitat Wien
-
-
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 6R8
- 募集
- Iwk Health Centre
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- 募集
- London Health Sciences Centre Victoria Hospital
-
Toronto、Ontario、カナダ、M5G 1X8
- 募集
- Hospital For Sick Children
-
-
-
-
-
Córdoba、スペイン、14004
- 募集
- Hosp Reina Sofia
-
Sabadell、スペイン、8208
- 募集
- Corporacio Sanitari Parc Tauli
-
Valencia、スペイン、46026
- 募集
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Nordbyhagen、ノルウェー、1474
- 募集
- Akershus Universitetssykehus HF
-
Oslo、ノルウェー、424
- 募集
- Oslo University Hospital
-
Tromsø、ノルウェー、9038
- 募集
- Universitetssykehuset Nord-Norge HF
-
Trondheim、ノルウェー、7030
- 募集
- St. Olavs Hospital
-
-
-
-
-
Amiens、フランス、80054
- 募集
- CHU Amiens-Hopital Nord
-
Lille、フランス、59037
- 募集
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris、フランス、75019
- 募集
- Hôpital Robert Debré
-
Paris、フランス、75015
- 募集
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Campinas、ブラジル、13060-904
- 募集
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba、ブラジル、80250-060
- 募集
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia、ブラジル、74605-020
- 募集
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre、ブラジル、90035-074
- 募集
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre、ブラジル、90035-007
- 募集
- Hospital De Clinicas De Porto Alegre
-
Vitória、ブラジル、29040-091
- 募集
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga、ブラジル、100000
- 募集
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Brussels、ベルギー、1090
- 募集
- Universitair Ziekenhuis Brussel
-
Brussels、ベルギー、1200
- 募集
- Cliniques Universitaires Saint Luc
-
Ghent、ベルギー、9000
- 募集
- Universitair Ziekenhuis Gent
-
Leuven、ベルギー、3000
- 募集
- UZ Leuven
-
-
-
-
-
Braga、ポルトガル、4710-243
- 募集
- Hospital de Braga
-
Lisbon、ポルトガル、1649-035
- 募集
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto、ポルトガル、4200-319
- 募集
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Rzeszów、ポーランド、35-302
- 募集
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw、ポーランド、04 501
- 募集
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw、ポーランド、04 730
- 募集
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Hirosaki、日本、036-8563
- 募集
- Hirosaki University Hospital
-
Kagoshima、日本、890-8544
- 募集
- Kagoshima University Hospital
-
Kashiwa-shi、日本、277-0871
- 募集
- Tsujinaka Hospital Kashiwanoha
-
Kobe、日本、650 0017
- 募集
- Kobe University Hospital
-
Saga、日本、849-8501
- 募集
- Saga University Hospital
-
Sendai、日本、989-3126
- 募集
- Miyagi Childrens Hospital
-
Setagaya Ku、日本、157 8535
- 募集
- National Center for Child Health and Development
-
Tokyo、日本、113-8431
- 募集
- Juntendo University Hospital
-
Tsu、日本、514 8507
- 募集
- Mie University Hospital
-
Ube、日本、755-8505
- 募集
- Yamaguchi University Hospital
-
Yokohama、日本、232-0024
- 募集
- Yokohama City University Medical Center
-
Yokohama、日本、230-8765
- 募集
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Busan、韓国、48108
- 募集
- Inje University Haeundae Paik Hospital
-
Daegu、韓国、41404
- 募集
- Kyungpook National University Chilgok Hospital
-
Seoul、韓国、03080
- 募集
- Seoul National University Hospital
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center
-
Seoul、韓国、120-752
- 募集
- Severance Hospital Yonsei University Health System
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
他の名前:
Guselkumab will be administered intravenously.
他の名前:
|
|
実験的:Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
他の名前:
Guselkumab will be administered intravenously.
他の名前:
|
|
実験的:Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
他の名前:
Guselkumab will be administered intravenously.
他の名前:
|
|
実験的:Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
他の名前:
Guselkumab will be administered intravenously.
他の名前:
|
|
実験的:Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
他の名前:
Guselkumab will be administered intravenously.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
時間枠:Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
時間枠:Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
時間枠:Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
時間枠:Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
時間枠:Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
時間枠:Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
時間枠:Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
時間枠:Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
時間枠:Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
時間枠:From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
時間枠:At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
時間枠:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
時間枠:Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
時間枠:Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CR109212
- 2021-006282-37 (EudraCT番号)
- CNTO1959PBCRD3007 (その他の識別子:Janssen Research & Development, LLC)
- 2023-504735-41-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。